Press Releases Vigil Neuroscience, Inc.

Equities

VIGL

US92673K1088

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
3.03 ^USD	+10.58%		+11.81%	-10.36%

Apr. 17	Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	CI
Mar. 26	Wedbush Trims Vigil Neuroscience Price Target to $22 From $23, Maintains Outperform Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting	Apr. 17	GL
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 26	GL
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer	Mar. 20	GL
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer	Mar. 20	AQ
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting	Mar. 13	GL
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting	Mar. 13	AQ
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days	Mar. 12	GL
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024	Mar. 06	GL
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024	Feb. 29	GL
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024	Feb. 29	AQ
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference	Feb. 07	GL
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones	Jan. 03	GL
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference	Nov. 22	GL
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference	Nov. 22	AQ
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE	Nov. 16	GL
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 07	GL
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease	23-10-17	GL
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease	23-10-17	AQ
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit	23-10-05	GL
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit	23-10-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vigil Neuroscience, Inc.

Equities

VIGL

US92673K1088

Press Releases

Filters